• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    EVP and Chief Legal Officer Katz David Jeffrey sold $1,161,270 worth of shares (17,000 units at $68.31), decreasing direct ownership by 16% to 86,774 units (SEC Form 4)

    8/15/25 8:00:13 AM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Katz David Jeffrey

    (Last) (First) (Middle)
    C/O RADNET, INC.
    1510 COTNER AVE.

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RadNet, Inc. [ RDNT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP and Chief Legal Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/13/2025 S 17,000 D $68.31(1) 86,774 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.02 to $68.54.
    /s/ Jose Gamez, Attorney-in-Fact 08/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RDNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    8/12/2021Outperform → Market Perform
    Raymond James
    More analyst ratings

    $RDNT
    SEC Filings

    View All

    SEC Form 10-Q filed by RadNet Inc.

    10-Q - RadNet, Inc. (0000790526) (Filer)

    8/11/25 4:37:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    8/11/25 6:09:19 AM ET
    $RDNT
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by RadNet Inc.

    EFFECT - RadNet, Inc. (0000790526) (Filer)

    7/30/25 12:15:13 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an i

    8/12/25 11:09:00 AM ET
    $BFLY
    $CLOV
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Biotechnology: Biological Products (No Diagnostic Substances)

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in

    8/10/25 4:00:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™

    TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertiseRadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT) and global leader in AI-powered health informatics, announced today that it h

    8/7/25 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Legal Officer Katz David Jeffrey sold $1,161,270 worth of shares (17,000 units at $68.31), decreasing direct ownership by 16% to 86,774 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    8/15/25 8:00:13 AM ET
    $RDNT
    Medical Specialities
    Health Care

    EVP, Chief Science Officer Sorensen Alma Gregory gifted 5,600 shares, decreasing direct ownership by 0.48% to 1,165,345 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/18/25 4:15:24 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Director Swartz David L was granted 2,699 shares, increasing direct ownership by 2% to 176,766 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/11/25 6:58:58 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Barclays with a new price target

    Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously

    9/6/24 7:50:42 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in

    8/10/25 4:00:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

    LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&

    7/25/25 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care